Report No. 2: Follow-up on the Use of Convupidiol® in Patients with Refractory (Drug-Resistant) Epilepsy
02/05/2023

Marketing Authorization Holder (MAH): ALEF
Pharmacovigilance Team
Date: December 2022

Download PDF here

Share:

Back